These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 27707887)
1. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887 [TBL] [Abstract][Full Text] [Related]
2. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. Dong X; Fernandez-Salas E; Li E; Wang S Neoplasia; 2016 Mar; 18(3):162-71. PubMed ID: 26992917 [TBL] [Abstract][Full Text] [Related]
3. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. Tani T; Yasuda H; Hamamoto J; Kuroda A; Arai D; Ishioka K; Ohgino K; Miyawaki M; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K Mol Cancer Ther; 2016 Jan; 15(1):162-71. PubMed ID: 26682573 [TBL] [Abstract][Full Text] [Related]
4. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Yamaguchi N; Lucena-Araujo AR; Nakayama S; de Figueiredo-Pontes LL; Gonzalez DA; Yasuda H; Kobayashi S; Costa DB Lung Cancer; 2014 Jan; 83(1):37-43. PubMed ID: 24199682 [TBL] [Abstract][Full Text] [Related]
6. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041 [TBL] [Abstract][Full Text] [Related]
7. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641 [TBL] [Abstract][Full Text] [Related]
8. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853 [TBL] [Abstract][Full Text] [Related]
9. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422 [TBL] [Abstract][Full Text] [Related]
10. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571 [TBL] [Abstract][Full Text] [Related]
11. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Santarpia M; Daffinà MG; D'Aveni A; Marabello G; Liguori A; Giovannetti E; Karachaliou N; Gonzalez Cao M; Rosell R; Altavilla G Drug Des Devel Ther; 2017; 11():2047-2063. PubMed ID: 28740365 [TBL] [Abstract][Full Text] [Related]
12. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. Taniguchi H; Takeuchi S; Fukuda K; Nakagawa T; Arai S; Nanjo S; Yamada T; Yamaguchi H; Mukae H; Yano S Cancer Sci; 2017 Jan; 108(1):53-60. PubMed ID: 27783866 [TBL] [Abstract][Full Text] [Related]
13. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242 [TBL] [Abstract][Full Text] [Related]
14. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib. Zhu VW; Cui JJ; Fernandez-Rocha M; Schrock AB; Ali SM; Ou SI Lung Cancer; 2017 Aug; 110():32-34. PubMed ID: 28676215 [TBL] [Abstract][Full Text] [Related]
15. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Lin YT; Yu CJ; Yang JC; Shih JY Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468 [TBL] [Abstract][Full Text] [Related]
16. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536 [TBL] [Abstract][Full Text] [Related]
17. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788 [TBL] [Abstract][Full Text] [Related]
18. ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC. Luukkainen MEK; Koivunen JP Anticancer Res; 2024 Jul; 44(7):2805-2813. PubMed ID: 38925827 [TBL] [Abstract][Full Text] [Related]
19. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627 [TBL] [Abstract][Full Text] [Related]
20. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. Kwon JH; Kim KJ; Sung JH; Suh KJ; Lee JY; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Kim S; Yoon SS; Lee JS Cells; 2019 Nov; 8(12):. PubMed ID: 31795298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]